Rémi Droller

Rémi Droller has a master’s degree in Molecular Biology (Paris VI) and master’s degree in Finance and Innovation Management (Masternova – AgroPariTech). He started at CDC Innovation from 2000 to 2003 and later joined AGF Private Equity (now Idinvest Partners), where he developed investment activity in life sciences and made investments such as Novagali Pharma (listed on Euronext and acquired by Santen), Prosensa Therapeutics (listed on Nasdaq and acquired by Biomarin), Vivacta (acquired by Novartis), IntegraGen (listed on Alternext), and Onxeo (listed on Euronext). Rémi joined Kurma Partners in 2010 and is in charge of investments in AM Pharma (The Netherlands), Orphazyme (Denmark), Oxthera (Sweden), Stat Diagnostica (Spain), Step Pharma (France), and Zealand Pharma (Denmark).